● Recruiting

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

Condition: HR+/HER2- Breast Cancer · HR+, HER2-, Advanced Breast Cancer · Sponsor: Avenzo Therapeutics, Inc.

PhasePhase 1/Phase 2

Planned participants380

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).

This description comes directly from the study's public registry record.

Talk to the study team

Medical Information · (858) 239-2944 · ClinicalTrials@avenzotx.com

Always discuss trial participation with your own doctor first.

Locations (15)

Avenzo Therapeutics Recruiting Site	Los Angeles, California, United States	Recruiting
Avenzo Therapeutics Recruiting Site	Los Angeles, California, United States	Recruiting
Avenzo Therapeutics Recruiting Site	New Haven, Connecticut, United States	Recruiting
Avenzo Therapeutics Recruiting Site	Orlando, Florida, United States	Recruiting
Avenzo Therapeutics Recruiting Site	Sarasota, Florida, United States	Recruiting
Avenzo Therapeutics Recruiting Site	Tampa, Florida, United States	Recruiting
Avenzo Therapeutics Recruiting Site	Boston, Massachusetts, United States	Recruiting
Avenzo Therapeutics Recruiting Site	New York, New York, United States	Recruiting
Avenzo Therapeutics Recruiting Site	Cleveland, Ohio, United States	Recruiting
Avenzo Therapeutics Recruiting Site	Columbus, Ohio, United States	Recruiting
Avenzo Therapeutics Recruiting Site	Nashville, Tennessee, United States	Recruiting
Avenzo Therapeutics Recruiting Site	Fort Worth, Texas, United States	Recruiting

+ 3 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06998407